Cargando…

(18)F-FSPG PET imaging for the evaluation of indeterminate pulmonary nodules

BACKGROUND: (18)F-fluorodeoxyglucose (FDG) PET/CT is recommended for evaluation of intermediate-risk indeterminate pulmonary nodules (IPNs). While highly sensitive, the specificity of FDG remains suboptimal for differentiating malignant from benign nodules, particularly in areas where fungal lung di...

Descripción completa

Detalles Bibliográficos
Autores principales: Paez, Rafael, Shah, Chirayu, Cords, Angelina J., Muterspaugh, Anel, Helton, John E., Antic, Sanja, Eisenberg, Rosana, Chen, Heidi, Grogan, Eric L., Manning, Henry C., Walker, Ronald C., Massion, Pierre P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926263/
https://www.ncbi.nlm.nih.gov/pubmed/35294486
http://dx.doi.org/10.1371/journal.pone.0265427
_version_ 1784670203034992640
author Paez, Rafael
Shah, Chirayu
Cords, Angelina J.
Muterspaugh, Anel
Helton, John E.
Antic, Sanja
Eisenberg, Rosana
Chen, Heidi
Grogan, Eric L.
Manning, Henry C.
Walker, Ronald C.
Massion, Pierre P.
author_facet Paez, Rafael
Shah, Chirayu
Cords, Angelina J.
Muterspaugh, Anel
Helton, John E.
Antic, Sanja
Eisenberg, Rosana
Chen, Heidi
Grogan, Eric L.
Manning, Henry C.
Walker, Ronald C.
Massion, Pierre P.
author_sort Paez, Rafael
collection PubMed
description BACKGROUND: (18)F-fluorodeoxyglucose (FDG) PET/CT is recommended for evaluation of intermediate-risk indeterminate pulmonary nodules (IPNs). While highly sensitive, the specificity of FDG remains suboptimal for differentiating malignant from benign nodules, particularly in areas where fungal lung diseases are prevalent. Thus, a cancer-specific imaging probe is greatly needed. In this study, we tested the hypothesis that a PET radiotracer (S)-4-(3-[(18)F]-fluoropropyl)-L-glutamic acid (FSPG) improves the diagnostic accuracy of IPNs compared to (18)F-FDG PET/CT. METHODS: This study was conducted at a major academic medical center and an affiliated VA medical center. Twenty-six patients with newly discovered IPNs 7-30mm diameter or newly diagnosed lung cancer completed serial PET/CT scans utilizing (18)F-FDG and (18)F-FSPG, without intervening treatment of the lesion. The scans were independently reviewed by two dual-trained diagnostic radiology and nuclear medicine physicians. Characteristics evaluated included quantitative SUVmax values of the pulmonary nodules and metastases. RESULTS: A total of 17 out of 26 patients had cancer and 9 had benign lesions. (18)F-FSPG was negative in 6 of 9 benign lesions compared to 7 of 9 with (18)F-FDG. (18)F-FSPG and (18)F-FDG were positive in 14 of 17 and 12 of 17 malignant lesions, respectively. (18)F-FSPG detected brain and intracardiac metastases missed by (18)F-FDG PET in one case, while (18)F-FDG detected a metastasis to the kidney missed by (18)F-FSPG. CONCLUSION: In this pilot study, there was no significant difference in overall diagnostic accuracy between (18)F-FSPG and (18)F-FDG for the evaluation of IPNs and staging of lung cancer. Additional studies will be needed to determine the clinical utility of this tracer in the management of IPNs and lung cancer.
format Online
Article
Text
id pubmed-8926263
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-89262632022-03-17 (18)F-FSPG PET imaging for the evaluation of indeterminate pulmonary nodules Paez, Rafael Shah, Chirayu Cords, Angelina J. Muterspaugh, Anel Helton, John E. Antic, Sanja Eisenberg, Rosana Chen, Heidi Grogan, Eric L. Manning, Henry C. Walker, Ronald C. Massion, Pierre P. PLoS One Research Article BACKGROUND: (18)F-fluorodeoxyglucose (FDG) PET/CT is recommended for evaluation of intermediate-risk indeterminate pulmonary nodules (IPNs). While highly sensitive, the specificity of FDG remains suboptimal for differentiating malignant from benign nodules, particularly in areas where fungal lung diseases are prevalent. Thus, a cancer-specific imaging probe is greatly needed. In this study, we tested the hypothesis that a PET radiotracer (S)-4-(3-[(18)F]-fluoropropyl)-L-glutamic acid (FSPG) improves the diagnostic accuracy of IPNs compared to (18)F-FDG PET/CT. METHODS: This study was conducted at a major academic medical center and an affiliated VA medical center. Twenty-six patients with newly discovered IPNs 7-30mm diameter or newly diagnosed lung cancer completed serial PET/CT scans utilizing (18)F-FDG and (18)F-FSPG, without intervening treatment of the lesion. The scans were independently reviewed by two dual-trained diagnostic radiology and nuclear medicine physicians. Characteristics evaluated included quantitative SUVmax values of the pulmonary nodules and metastases. RESULTS: A total of 17 out of 26 patients had cancer and 9 had benign lesions. (18)F-FSPG was negative in 6 of 9 benign lesions compared to 7 of 9 with (18)F-FDG. (18)F-FSPG and (18)F-FDG were positive in 14 of 17 and 12 of 17 malignant lesions, respectively. (18)F-FSPG detected brain and intracardiac metastases missed by (18)F-FDG PET in one case, while (18)F-FDG detected a metastasis to the kidney missed by (18)F-FSPG. CONCLUSION: In this pilot study, there was no significant difference in overall diagnostic accuracy between (18)F-FSPG and (18)F-FDG for the evaluation of IPNs and staging of lung cancer. Additional studies will be needed to determine the clinical utility of this tracer in the management of IPNs and lung cancer. Public Library of Science 2022-03-16 /pmc/articles/PMC8926263/ /pubmed/35294486 http://dx.doi.org/10.1371/journal.pone.0265427 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication.
spellingShingle Research Article
Paez, Rafael
Shah, Chirayu
Cords, Angelina J.
Muterspaugh, Anel
Helton, John E.
Antic, Sanja
Eisenberg, Rosana
Chen, Heidi
Grogan, Eric L.
Manning, Henry C.
Walker, Ronald C.
Massion, Pierre P.
(18)F-FSPG PET imaging for the evaluation of indeterminate pulmonary nodules
title (18)F-FSPG PET imaging for the evaluation of indeterminate pulmonary nodules
title_full (18)F-FSPG PET imaging for the evaluation of indeterminate pulmonary nodules
title_fullStr (18)F-FSPG PET imaging for the evaluation of indeterminate pulmonary nodules
title_full_unstemmed (18)F-FSPG PET imaging for the evaluation of indeterminate pulmonary nodules
title_short (18)F-FSPG PET imaging for the evaluation of indeterminate pulmonary nodules
title_sort (18)f-fspg pet imaging for the evaluation of indeterminate pulmonary nodules
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926263/
https://www.ncbi.nlm.nih.gov/pubmed/35294486
http://dx.doi.org/10.1371/journal.pone.0265427
work_keys_str_mv AT paezrafael 18ffspgpetimagingfortheevaluationofindeterminatepulmonarynodules
AT shahchirayu 18ffspgpetimagingfortheevaluationofindeterminatepulmonarynodules
AT cordsangelinaj 18ffspgpetimagingfortheevaluationofindeterminatepulmonarynodules
AT muterspaughanel 18ffspgpetimagingfortheevaluationofindeterminatepulmonarynodules
AT heltonjohne 18ffspgpetimagingfortheevaluationofindeterminatepulmonarynodules
AT anticsanja 18ffspgpetimagingfortheevaluationofindeterminatepulmonarynodules
AT eisenbergrosana 18ffspgpetimagingfortheevaluationofindeterminatepulmonarynodules
AT chenheidi 18ffspgpetimagingfortheevaluationofindeterminatepulmonarynodules
AT groganericl 18ffspgpetimagingfortheevaluationofindeterminatepulmonarynodules
AT manninghenryc 18ffspgpetimagingfortheevaluationofindeterminatepulmonarynodules
AT walkerronaldc 18ffspgpetimagingfortheevaluationofindeterminatepulmonarynodules
AT massionpierrep 18ffspgpetimagingfortheevaluationofindeterminatepulmonarynodules